Dr. Crombez joined Ultragenyx following the acquisition of Dimension Therapeutics in November 2017. As Chief Medical Officer and Executive Vice President, Dr. Crombez is responsible for strategic leadership of the clinical development and translational research programs, and oversees global development functions including Clinical Development, Clinical Operations, BioMetrics, Endpoint Development and Strategy, Regulatory Affairs and Drug Safety/Pharmacovigilance.
Previously, Dr. Crombez served as Ultragenyx’s Chief Medical Officer for gene therapy and inborn errors of metabolism, overseeing global clinical development and execution for the company’s gene therapy programs. At Dimension Therapeutics, Dr. Crombez served as Chief Medical Officer and led the clinical development efforts for clinical gene therapy programs in hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency and glycogen storage disease type Ia (GSDIa). Previously, he worked at Shire in its Human Genetics Therapy business unit.
Dr. Crombez is an appointed industry representative on the FDA Cellular, Tissue and Gene Therapies Advisory Committee. Before joining industry, he was assistant professor, Department of Pediatrics, Division of Medical Genetics at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA).
Dr. Crombez is a board-certified clinical geneticist and completed residencies in pediatrics and medical genetics and a fellowship in clinical biochemical genetics at the UCLA School of Medicine. Dr. Crombez obtained his B.S. degree in biology from the University of Michigan, Ann Arbor, and his M.D. degree from Wayne State University School of Medicine, Detroit.
What is Eric Crombez's net worth?
The estimated net worth of Eric Crombez is at least $2.30 million as of April 18th, 2024. Dr. Crombez owns 48,785 shares of Ultragenyx Pharmaceutical stock worth more than $2,304,603 as of November 23rd. This net worth estimate does not reflect any other assets that Dr. Crombez may own. Learn More about Eric Crombez's net worth.
How do I contact Eric Crombez?
Has Eric Crombez been buying or selling shares of Ultragenyx Pharmaceutical?
Eric Crombez has not been actively trading shares of Ultragenyx Pharmaceutical during the past quarter. Most recently, Eric Crombez sold 142 shares of the business's stock in a transaction on Thursday, April 18th. The shares were sold at an average price of $44.10, for a transaction totalling $6,262.20. Following the completion of the sale, the executive vice president now directly owns 48,785 shares of the company's stock, valued at $2,151,418.50. Learn More on Eric Crombez's trading history.
Who are Ultragenyx Pharmaceutical's active insiders?
Ultragenyx Pharmaceutical's insider roster includes William Aliski (Director), Camille Bedrosian (EVP), Eric Crombez (Chief Medical Officer and EVP), Mardi Dier (CFO), Matthew Fust (Director), Erik Harris (EVP), Howard Horn (CFO and EVP, Corporate Strategy), Dennis Huang (EVP), Theodore Huizenga (CAO), Emil Kakkis (CEO), Thomas Kassberg (EVP), Karah Parschauer (EVP), John Pinion (Insider), Corsee Sanders (Director), Shalini Sharp (CFO), and Clay Siegall (Director). Learn More on Ultragenyx Pharmaceutical's active insiders.
Are insiders buying or selling shares of Ultragenyx Pharmaceutical?
During the last twelve months, insiders at the biopharmaceutical company sold shares 13 times. They sold a total of 91,799 shares worth more than $4,701,943.08. The most recent insider tranaction occured on October, 10th when CFO Howard Horn sold 7,465 shares worth more than $393,853.40. Insiders at Ultragenyx Pharmaceutical own 5.8% of the company.
Learn More about insider trades at Ultragenyx Pharmaceutical. Information on this page was last updated on 10/10/2024.
